Diagnosed prevalent cases of multiple sclerosis to increase by 0.19 per cent AGR in 7MM during…
GlobalData report highlights rising diagnosed prevalence of multiple sclerosis in the US, with middle-aged adults showing the…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
GlobalData
Biopharma innovation meets market headwinds tempering optimism: GlobalData
GlobalData’s report captures a moment for the global biopharmaceutical sector, where the pace of innovation is clashing with a…
Trump’s move to transform US pharma manufacturing raises doubts over its effectiveness: GlobalData
GlobalData analysts highlight uncertainty around new FDA directives as pharma giants ramp up US-based manufacturing investments…
PureTech’s LYT-100 holds potential to expand treatment options for idiopathic pulmonary fibrosis:…
As current IPF treatments face adoption and efficacy challenges, GlobalData highlights LYT-100’s potential to address unmet needs…
Sibeprenlimab’s priority review highlights potential to differentiate in IgAN space
Interim results showed that sibeprenlimab demonstrated a statistically significant and clinically meaningful reduction in 24-hour…
GlobalData forecasts ADC NSCLC market to reach $3.9 bn in 2032
GlobalData’s patient-based forecast highlights that ADCs will see significant sales in the NSCLC space by 2032, led by…
China’s biopharma commands $30 billion in oncology licensing deals, triples US output in 2024
Significant reforms in clinical development processes and regulatory reviews in China have led to faster drug approvals,…
KDCA, SK bioscience launch support programme to shield South Korea against future pandemic influenza…
This government-led initiative focuses on developing vaccines against avian influenza that are identified as high-risk candidates…
Real-world data backs anti-IL-5 use in COPD with comorbid asthma
GlobalData’s latest analysis highlights the results of a retrospective study from Ghent University Hospital based on Belgian…
Tezepelumab’s trial results strengthen potential for biomarker-driven biologic therapies in COPD:…
GlobalData’s latest analysis reveals that tezepelumab, evaluated in the Phase IIa COURSE trial, achieved a 26 per cent reduction…